| Document |
Document Title |
|
WO/2014/057080A2 |
The present invention is directed to novel cyclic amines which inhibit the P2X7 receptor.
|
|
WO/2014/056760A1 |
The present application relates to agents for dyeing keratin fibers, in particular human hair, the agent containing, in a cosmetic carrier, at least a compound of formula (I).
|
|
WO/2014/056758A1 |
The present application relates to agents for dyeing keratin fibers, in particular human hair, the agent containing, in a cosmetic carrier, a) at least one compound of formula (I) and/or a physiologically compatible salt of this compound...
|
|
WO/2014/053595A1 |
This invention relates to acylaminopyrimidine derivatives of formula (I), processes for their preparation, pharmaceutical compositions, and their use in therapy.
|
|
WO/2014/053694A1 |
Compounds of formula I, wherein A, B, X, Z and R1-R6, are as defined in the claims, exhibit TRPA 1 activity and are thus useful as TRPA1 modulators.
|
|
WO/2014/048065A1 |
Provided are triazole derivatives of Formula I which are potent inhibitors of spleen tyrosine kinase and pharmaceutical composition. The triazole derivatives are useful in the treatment and prevention of diseases mediated by said enzyme,...
|
|
WO/2014/048532A1 |
Compounds of the formula (I) in which R1, R2, R3, X1, X2 and Y have the meanings indicated in Claim 1, are inhibitors of Tankyrase, and can be employed, inter alia, for the treatment of diseases such as cancer, cardiovascular diseases, c...
|
|
WO/2014/050874A1 |
Provided is a novel crystal of rosuvastatin calcium that exhibits suitable properties as a medicine. The present invention provides a TW-1 crystal of rosuvastatin calcium having a powder X-ray diffraction pattern that exhibits a characte...
|
|
WO/2014/047996A1 |
Provided is a new crystalline form of methyl (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfon
yl)amino] pyrimidin-5-yl](3R,5S)-3,5-dihydroxy-6-heptenoate and preparation method thereof. The preparation method can obtain the c...
|
|
WO/2014/047707A1 |
The present invention relates to a compound of formula (I) or to a pharmaceutically acceptable salt thereof with analgesic activity. In particular, the compounds according to the present invention are useful for treating or preventing ac...
|
|
WO/2014/051056A1 |
The purpose of the present invention is to provide: crystals of (S,E)-2-(2,6-dichlorobenzamido)-5-[4-(isopropyl- pyrimidin-2-ylamino)phenyl]pent-4-enoic acid having excellent chemical and physical stability or a pharmacologically accepta...
|
|
WO/2014/049578A1 |
The present invention relates to a compound of formula (I): wherein A and A' independently represent a phenylene group or a pyridylene group; R2 is a hydrogen atom or a (C1-C4)alkyl group; R3 is a 2-pyridyl group, 3-pyridyl group, a 4-py...
|
|
WO/2014/047232A2 |
Compounds having a c-Rel inhibiting property according to the formula: (1) wherein R1 and R2 are each independently selected from hydrogen atom and hydrocarbon groups having at least one and up to thirty carbon atoms and optionally subst...
|
|
WO/2014/045029A1 |
The present invention relates to compounds of formula (Ia), (Ib) or (Ic): to pharmaceutically acceptable salts therefore and to pharmaceutically acceptable solvates of said compounds and salts, wherein the substituents are defined herein...
|
|
WO/2014/040555A1 |
The present invention relates to compounds as represented by general formula (I) as tyrosine kinase inhibitors, preparation method thereof, pharmaceutical compositions containing the compounds, and uses thereof for preventing and/or trea...
|
|
WO/2014/039714A2 |
Compounds active on c-kit protein kinases or mutant c-kit protein kinases having any mutations are described, as well as methods of making and using such compounds to treat diseases and conditions associated with aberrant activity of the...
|
|
WO/2014/037961A1 |
Provided is a process for preparation of Crystalline Erlotinib HCl Form-SE characterized by X-ray powder diffraction pattern comprising at least 5 characteristic 2θ° peaks selected from the XRPD peak set of 5.60, 10.00, 11.40, 13.00, 1...
|
|
WO/2014/036766A1 |
Provided is a smectic phase A liquid crystal material, comprising a heterocyclic compound; the heterocycle is a nitrogen-containing heterocycle formed by replacing 1-4 carbon atoms in a benzene ring with nitrogen atoms, or a heterocycle ...
|
|
WO/2014/036022A1 |
Compounds of Formula I are useful inhibitors of tankyrase. Compounds of Formula I have the following structure: where the definitions of the variables are provided herein.
|
|
WO/2014/029007A1 |
The present invention relates to a novel family of inhibitors of protein kinases. In particular, the present invention relates to inhibitors of the members of the Tec and Src protein kinase families, more particularly Btk, having the gen...
|
|
WO/2014/031571A1 |
Compounds that inhibit the replication of negative-sense, single-stranded RNA viruses, such as influenza virus, vesicular stomatitis virus (VSV), and Newcastle disease virus (NDV), and the use of those compounds for the treatment or inhi...
|
|
WO/2014/030743A1 |
Provided is a compound which has an excellent FLAP inhibitory activity and is useful as a prophylactic or therapeutic agent for arteriosclerosis and the like, or a salt of the compound. The present invention relates to a compound represe...
|
|
WO/2014/026242A1 |
This invention relates to compounds of the formula (I). The invention also relates to processes for the preparation of the compound of the formula (I), pharmaceutical agents or compositions containing the compound or a method of using th...
|
|
WO/2014/026243A1 |
This invention relates to a compound of the formula (I): The invention also relates to processes for the preparation of the compound of the formula (I), pharmaceutical agents or compositions containing the compound or a method of using t...
|
|
WO/2014/028669A1 |
The present invention relates to aryl sulfones and related compounds that are modulators of ROR-gamma receptors. The invention also provides pharmaceutical compositions comprising these modulators, and methods of modulating ROR-gamma rec...
|
|
WO/2014/028914A1 |
The invention relates to novel deuterated Icotinib derivatives and their pharmaceutically acceptable salts, solvates, and prodrugs thereof. This invention also provides compositions comprising any of the deuterated Icotinib derivatives a...
|
|
WO/2014/023027A1 |
Disclosed in the present invention are an Erlotinib hydrochloride polymorph and the preparation method therefor. In particular, disclosed in the present invention are an Erlotinib hydrochloride semihydrate polymorph with a purity ≥95% ...
|
|
WO/2014/023681A1 |
A process for the preparation of 4,6-dihalopyrimidin-5-aminesof formula (II), or salts thereof, which comprises reacting 5-aminopyrimidin-4,6-diols of formula (III), or salts thereof, or a solvate either of the compound of formula (III) ...
|
|
WO/2014/023691A1 |
The present invention relates to a compound having the general formula (Di), (Dii), or (Diii), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, codrug, cocrystal, prodrug, tautomer, racemate, enantiomer, ...
|
|
WO/2014/023813A1 |
This invention relates to alkylpyrimidine derivatives of formula (I), processes for their preparation, phamaceutical compositions, and their use in therapy for the treatment of viral infections.
|
|
WO/2014/026009A2 |
The application describes targets and methods that can inhibit bacterial growth in Gram-positive and Gram-negative bacteria. A bacterial enzyme, 2-epimerase, is common to both Gram-positive and Gram-negative bacteria and contains an allo...
|
|
WO/2014/023723A1 |
The invention relates to compounds of the general formula (I), wherein the variable have the meanings as indicated in the claims, or a physiologically acceptable salt thereof. The active ingredients have advantageous pesticidal propertie...
|
|
WO/2014/019186A1 |
Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated b...
|
|
WO/2014/022728A1 |
The present application provides novel substituted quinazoline and pyrido-pyrimidine compounds of formula (I) and pharmaceutically acceptable salts, prodrugs, and solvates thereof. Also provided are methods for preparing these compounds....
|
|
WO/2014/019023A1 |
The present invention relates to chemical compounds of formula (I), with the substituents as described in the specification, useful in the positive modulation of the alpha 7 nicotinic acetylcholine receptor (α7 nAChR). The invention als...
|
|
WO/2014/015935A2 |
The present invention concerns particular fluorenes, the use of the compound in an electronic device, and an electronic device containing at least one of these compounds. The present invention further concerns a method for producing the ...
|
|
WO/2014/016314A1 |
A compound having the formula (I), for use in treating a disease; a composition comprising said fused quinonic compound of formula (I) and at least one pharmaceutically acceptable carrier; as well as a method of modulating a Janus Kinase...
|
|
WO/2014/017569A1 |
A pharmaceutical product for lowering blood LDL, which is a pharmaceutical product that contains a compound represented by formula (I) as an active ingredient, said compound having actions of inhibiting the expression of PCSK9mRNA, lower...
|
|
WO/2014/015054A1 |
Disclosed herein are novel pharmaceutical agents which are useful as integrin receptor antagonists that mediate the pathologic processes of angiogenesis and fibrosis and as such are useful in pharmaceutical compositions and in methods fo...
|
|
WO/2014/014310A1 |
The present invention relates to a specific combination of a dopant compound and a host compound, and an organic electroluminescent device comprising the same. The organic electroluminescent device of the present invention emits yellow-g...
|
|
WO/2014/009872A1 |
Disclosed are compounds of formula (I), their tautomeric forms, stereoisomers, and pharmaceutically acceptable salts thereof, wherein R1-R6, R7a-d, R8a-d, A, M, n, and p are as defined in the specification, pharmaceutical compositions in...
|
|
WO/2014/009968A2 |
The present invention provides a commercially viable process for preparing rilpivirine and its pharmaceutically acceptable acid addition salts thereof in high yields using novel intermediate.
|
|
WO/2014/009318A1 |
The present invention relates to 3-{3-[1-(4-Dimethylaminomethyl- phenylamino)-1-phenyl-meth-(Z)-ylidene]-2-oxo-2,3-dihydro-1 H- indol-6-yll-propynoic acid ethylamide having the formula (I) below, to a process for the manufacture thereof,...
|
|
WO/2014/010748A1 |
The present invention relates to compounds of the Formula (I) and (II): wherein each variable is as defined in the specification, pharmaceutically acceptable salts and solvates thereof, as well as use of such compounds as a BACE1 inhibit...
|
|
WO/2014/008636A1 |
Macrocyclic compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein G, Q, W, X, Y, Z, R',R2,R3,R4,R5 and R6 are as defined herein are disclosed. Compositions comprising at least one macrocyclic compound, and metho...
|
|
WO/2014/011900A2 |
Described herein are inhibitors of FGFR, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions to inhibit the activity of tyrosine kinases.
|
|
WO/2014/010700A1 |
The purpose of the present invention is to provide: an amino compound of an amino acid derivative, a peptide or the like, which is produced by derivatizing a glycated protein decomposition product derivative including a final glycation p...
|
|
WO/2014/006071A1 |
The present invention relates to new indene derivatives having a great affinity for sigma receptors, especially sigma-1 receptors, as well as to the process for the preparation thereof, to compositions comprising them, and to their use a...
|
|
WO/2014/006518A1 |
The present disclosure relates to compound of structural "formula I" and a method for preparing a compound of structural formula I. The disclosure further relates to a method of arresting DNA double-strand break (DSB) repair by employing...
|
|
WO/2014/002105A1 |
The present invention relates to compounds of the general formula (I), their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods for their preparation, use ...
|
